Trial Profile
An Open-label, Multicenter, Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of UCB0942 When Used as Adjunctive Therapy for Partial-onset Seizures in Adult Subjects With Highly Drug-resistant Focal Epilepsy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Padsevonil (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions; Therapeutic Use
- Sponsors UCB; UCB Biopharma
- 23 Nov 2021 Status changed from completed to discontinued.
- 03 Dec 2020 Status changed from active, no longer recruiting to completed.
- 11 Sep 2020 Planned End Date changed from 1 Dec 2021 to 1 Nov 2020.